Trial Profile
A retrospective, observational, monocentric study evaluating acute kidney injury (AKI) in patients treated with vemurafenib for metastatic melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jul 2017
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 10 Jul 2017 New trial record